Retatrutide 20mg
20 mg
A triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied for its potential in metabolic regulation, appetite signalling, and energy expenditure research.
Select dosage
All Nova Labs products are intended solely for scientific laboratory research. Not for human use, consumption, or therapeutic application.
Research Benefits
Triple Receptor Activation
Targets GLP-1, GIP, and glucagon receptors simultaneously — the only triple-agonist currently in Phase 3 clinical research.
Metabolic Signalling
Studied for its influence on glucose metabolism, lipid profiles, and energy expenditure pathways.
Appetite Research
Investigated for modulation of satiety-related signalling across multiple hormonal pathways.
Body Composition
Phase 2 data indicates potential for significant fat mass reduction while preserving lean tissue.
